MSCs; migration; cell therapy; engraftment efficiency; neurological disorder Mesenchymal stromal/stem cells (MSCs) are multipotent cells under consideration as a potential new therapy for a variety of inflammatory diseases including certain neurological disorders. It is generally thought that the efficacy of cell therapy in attenuating damage after ischemia, inflammation, or injury depends on the quantity of transplanted cells recruited to the target tissue. However, only a small number of systematically infused MSCs can effectively migrate to target sites, which significantly decreases the efficacy of exogenous cell-based therapy. In this review, we discuss specific factors influencing MSC migration, and summarize current strategies that effectively promote the motility of MSCs. In addition, we describe several protocols to improve the migration of stromal cells into the nervous system and, therefore, enhance the efficiency of engraftment as means of treating neurological disorders.
Introduction
Stem cells are defined as the cells capable of self-renewal and differentiation into one or more specialized cell types [1] . Generally, two types of stem cells have been described: embryonic stem cells (ESCs) and adult stem cells. Although ESCs are pluripotent and can be used to replace any tissue, they may have teratogenic effects, and the procedure to isolate them is ethically controversial. Adult stem cells that have the ability to differentiate into mesodermal lineage tissues such as bone, fat, and cartilage are called mesenchymal stem/stromal cells (MSCs) [2] . It has been traditionally thought that MSCs reside mainly in bone marrow. However, MSCs have been recently obtained from various tissues including adipose tissue [3] , dental pulp [4] , synovium [5] , Wharton's jelly [6] , hair follicles [7] , and olfactory bulbs [8] .
Systemically administered MSCs are a promising tool in the development of regenerative medicine. These cells have the ability to migrate and accumulate at sites of injury and inflammation and promote functional recovery by replacing damaged tissue through paracrine effects, activating endogenous progenitor cells, and/or modulating immune responses [9, 10] . The application of MSCs in cell therapies has increased in recent years because of extensive availability of these cells, convenient isolation methods, less ethical concerns, and relatively low immunogenicity [11] . Numerous preclinical and clinical trials targeting various diseases, such as specific congenital defects, traumatic or ischemic injuries (e.g., tibial fracture, brain and spinal cord injury, liver injury, stroke, and myocardial infarction), immune disorders (arthritis, multiple sclerosis, diabetes mellitus, and Crohn's disease), degenerative diseases, and graft-versus-host disease (GVHD) [10] [11] [12] [13] [14] have been performed.
It is generally thought that the efficiency of MSC therapy in attenuating damage after ischemia, inflammation, or injuries mainly depends on the quantity of transplanted cells recruited to the target tissue [15] . Substantial evidence has shown that infused MSCs tend to migrate to the site of lesion. However, studies investigating the homing and the long-term engraftment of these cells finally showed that only a small percentage of cells were detectable in the lesions given that most cells became trapped in the liver, spleen, and lungs in animal models [16] [17] [18] . Regarding the central nervous system (CNS), even fewer systematically delivered cells home to the sites of ischemia or traumatic injury because of the blood brain barrier (BBB). The low rate of cell homing, retention, and survival is one of the major limitations in current experimental and clinical studies investigating the therapeutic potential of different types of MSCs [19] . Therefore, understanding the mechanisms of homing may be crucial for enhancing the engraftment efficiency, particularly in cases of intravenous or arterial cell administration. Karp and Leng Teo proposed the definition of MSC homing in 2009 [11] by referring to the active or positive arrest of MSCs within the vasculature of a tissue followed by transmigration across the endothelium. A series of complex steps are involved in the homing of MSCs. However, the mechanisms underlying the homing of exogenous and endogenous MSCs have not been clearly elucidated. This review will focus on factors determining the migration of MSCs and propose strategies to improve homing to the target tissue, with a particular focus on cell therapy for CNS disorders.
In vivo determinants of MSC migration
While the mechanisms underlying the homing of leukocytes to the sites of inflammation have been extensively described [20] [21] [22] , those underlying MSC homing to the sites of interest remain unknown. As in the case of leukocyte homing, recruitment and incorporation of MSCs into ischemic or injured tissue may also require a coordinated multistep process including adhesion to the endothelium, transendothelial migration, chemotaxis, matrix degradation and invasion, and in situ differentiation (see Figure 1 ). Integrin blocking and knockout studies provided evidence for dependence of MSC migration on selectin and integrin interactions [15, 23] . These results suggest that the engraftment of MSCs within target tissues depends on specific molecular interactions prior to the transmigration step [11] . Besides adhesive interactions that mediate MSC homing to specific sites, chemokines released from the tissue or endothelial cells may promote activation of adhesion ligands, transendothelial migration, chemotaxis, and/or subsequent retention in the surrounding tissue [24] [25] [26] . Specific chemokines and their receptors are essential for the migration of MSCs to the sites of inflammation and injury. In addition, MSCs secrete proteases (i.e., matrix metalloproteinases, MMPs) that regulate transmigration and invasion of the endothelial basement membrane and degrade extracellular matrix (ECM) during chemotaxis [11, 27, 28] .
Effects of chemo-attractants (chemokines and growth factors)
Chemokines are a family of small cytokines with a molecular weight of approximately 8-10 kD that act as chemoattractants to guide cell migration. Functional chemokine receptors CXCR1-7, CCR1-10, CX3CR1, and XCR1 are expressed by MSCs in vitro [29] . The migration of adipose-derived MSCs (AdMSCs) and bone marrowderived MSCs (BMSCs) is believed to occur in response to stimulation with various chemokines and cytokines. For example, the stromal-derived factor-1 (SDF-1)a/ CXCR4 interaction has been proven to affect the migration of MSCs in models of traumatic brain injury [30] , spinal cord injury [31] , myocardial infarction [32, 33] , acute lung injury [34] , and liver injury [14] . Akt, extracellular signal-regulated kinase (ERK), and p38 mitogen activated protein kinase (MAPK) signal transduction pathways may be involved in SDF-1-mediated migration of MSCs [33, 35] . In the rat model of bladder dysfunction, CXCL5/CXCR2 axis mediated chemotaxis of AdMSCs [36] . Monocyte chemoattractant protein-1 (MCP-1)/CCR2 signaling might promote the homing of MSCs to myocardium in dilated cardiomyopathy and a model of CNS inflammation [37, 38] . In addition, binding of fractalkine (CX3CL1) to CX3CR1 promotes chemotaxis of BMSCs towards ischemic brain lesions through Janus-Activated Kinase 2 (Jak2) signaling and cytoskeletal reorganization [39, 40] . However, certain studies have found that growth factors are more potent chemotactic agents than chemokines for human BMSCs and AdMSCs [26, 41] . Human adipose-derived MSCs (hAdMSCs) express transforming growth factor (TGF)-β receptor 2, tumor necrosis factor (TNF) receptor superfamily member 1A, platelet-derived growth factor (PDGF) receptor A, and PDGF receptor B at both protein and mRNA levels [26] . Moreover, PDGF-AB, TGF-β1, and TNF-α showed extraordinary chemoattractant activity in a transwell migration assay in vitro. A similar result was obtained for human bone marrow-derived MSCs (hBMSCs), as the growth factors PDGF-AB and insulin-like growth factor 1 (IGF-1) were demonstrated as the most potent chemoattractant, whereas the chemokines regulated on activation normal T cell expressed and secreted (RANTES) factor, macrophagederived chemokine (MDC), and SDF-1 had a limited effect on migration [25] . Besides, hBMSCs and umbilical cord blood derived MSCs (hUBMSCs) were strongly chemoattracted by hepatocyte growth factor (HGF) gradients in vitro, suggesting that HGF/Met might also play a role in the migration of MSCs [42] .
Effects of adhesion molecules (integrins and selectins)
Integrins are transmembrane receptors that function as the bridges for cell-cell and cell-extracellular matrix (ECM) interactions. The hMSCs were shown to express integrins alpha1, alpha2, alpha3, alpha5, alpha6, alphav, beta1, beta3, and beta4 [43] . The integrin ligand vascular cell adhesion molecule (VCAM)-1 is involved in the adhesion of MSCs to endothelial cells. Fischer et al. found that most intravenously-infused BMSCs became trapped inside the lungs, which was prevented by a pretreatment with anti-CD49d (also called very late antigen-4, VLA4, or α4β1) antibody [44] . The adhesion molecules VLA-4/VCAM-1 expressed by MSCs/ endothelial cells were shown to play a role in the interactions between MSCs and lung tissue [45] . In addition, the VLA-4/VCAM-1 receptor axis has also been shown to mediate MSC migration in myocardial infarction [46] . Intravital microscopy performed on the mice with chronic experimental autoimmune encephalomyelitis and injected with AdMSCs revealed that a relevant subset of AdMSCs expresses activated alpha 4 integrins and adheres to inflamed brain venules, while bioluminescence imaging showed that alpha 4 integrins control AdMSCs accumulation in inflamed CNS [47] . Selectins are a large family of cell adhesion molecules (or CAMs). They can bind to sugar moieties and are therefore classified as a type of lectin. Blocking P-or E-selectins and CD44 knockout tests showed that both P-and E-selectins are involved in the homing of BMSCs to the infarct site after ischemic stroke, with CD44 acting as the critical ligand for selectin-mediated BMSC recruitment [48, 49] . However, it has also been shown that human MSCs express a CD44 glycoform bearing alpha-2,3-sialyl modifications [50] , but not E-selectin ligands, which may provide new insights for glycoengineering strategies as means to improve the migration of the MSCs.
Effects of enzymes
Besides chemokines and adhesion molecules, enzymes secreted by certain invasive cells are essential for their migratory activity. During chemotaxis, MSCs secrete proteases that regulate transmigration and invasion of the endothelial basement membrane and degrade the extracellular matrix (ECM) [11] . MMPs are a family of zinc-dependent proteolytic enzymes that play an essential role in regulating the migratory activity of transplanted cells. The degradation products of ECM proteolysis by MMPs also mediate cell migration [51] . Several studies have shown that BMSCs highly express MMP-2, MT1-MMP (membrane-type MMP), tissuespecific inhibitor of metalloproteinase (TIMP)-1, and TIMP-2 [52] . It was shown that MMP-2, MMP-9, MT1-MMP, and TIMP-2 could all promote the migration of MSCs, while TIMP-1 and TIMP-3 may have negative effects on cell motility [27] . In recent years, a new concept called biobridge has been proposed to elucidate the mechanism underlying the migration of endogenous progenitor cells to the lesion sites following MSCs therapy. Tajiri et al. used a model of traumatic brain injury and demonstrated that transplanted MSCs can form a biobridge connecting the area of injury to the neurogenic niche within the brain facilitating the repair by endogenous cells [53, 54] . Other studies hypothesized that, in a model of stroke [55, 56] , a similar biobridge by injected MSCs is formed between the neurogenic niche and the stroke core and peri-infarct area. It has been found that the biobridge expresses high levels of extracellular MMPs, and that these may play an important role in the migration of endogenous neural stem cells [53] .
In vitro determinants of MSC migration
The migration of MSCs to the target tissue can be influenced by a number of factors related to the preparation of cells for transplantation, such as cell culture conditions, the origin of the MSCs, the conditioning medium, and the route of administration. For example, increased culture confluence has been shown to inhibit transendothelial MSC migration by increasing the production of a natural MMP inhibitor, TIMP-3 [28] . Besides, increased number of cell passages can also affect the migration potential, as passaging the cells can modify the expression of receptors involved in the homing process [57] . MSCs of different origins may show differential motility due to differences in the expression profile of receptors and cell size [11] . Cheng et al. found that ASCs treated with high concentrations of glucose exhibited decreased cell migration in vitro [58] . Different administration routes may affect the efficacy of engraftment. Intravenous (IV) injection, intraperitoneal (IP) injection, intraarterial (IA) injection, and intracardiac (IC) injection are common methods of systematic administration. Although IV delivery is the least invasive one, most of the infused cells can become trapped in the liver, spleen, and lungs. Higher engraftment rates can be achieved by IC and IA delivery in certain models of myocardial infarction [59, 60] due to bypassing of filtration organs. In a model of acute stroke, IA stromal cell injection resulted in a highly variable efficacy of cerebral engraftment versus distant IV injection [61] . Although local infusion can be used to directly inject MSCs into the tissue of interest, this strategy is not clinically feasible because of its invasiveness (e.g., local injection into the heart or brain). Besides, locally administered cells often die before relieving the inflammatory response due to limitations in the diffusion of nutrients and oxygen [11] .
Strategies to improve MSC migration
Many trials have been conducted in recent years to investigate potential strategies aiming to improve the migration and homing of MSCs to the sites of injury and inflammation. These existing strategies can be summarized as follows:
Culturing MSCs under hypoxic conditions
Hypoxic preconditioning of MSCs has been proposed as a therapy for ischemic diseases [62] . Human MSCs exposed to hypoxic preconditioning have shown increased mobility and therapeutic potential compared to unconditioned control cells [63, 64] . The expression levels of CXCR4, CXCR7, CX3CR1, SDF-1a, and integrin αM [64] [65] [66] [67] increased when MSCs were exposed to hypoxic conditions. Although the underlying mechanism is not completely clear, hypoxia-inducible factor-1 alpha (HIF-1α) is considered the master regulator of the adaptive response to hypoxia [68] . It has been suggested that enhanced activation of Ras homolog gene family, member A (RhoA), focal adhesion kinase (FAK), and Phosphatidylinositol-3-Kinase (PI3K)/Akt-HIF-1α-CXCR4/CXCR7 pathway mediates the increase in cell migration induced by hypoxic pretreatment [66] [67] [68] [69] . These results suggest that short-term culture of MSCs under hypoxic conditions may provide novel means of enhancing their engraftment into a variety of tissues [70] . While hypoxic pretreatment is inexpensive and simple, the concentration of oxygen and the duration of hypoxia need to be further optimized to improve the therapeutic effect.
Pretreatment of MSCs with cytokines and small molecules
Prestimulating stromal cells with certain cytokines and small molecules in culture may facilitate their migration. The studies using an in vitro transwell assay showed that hAd-MSCs or hBMSCs prestimulated with TNF-a show increased migration compared with untreated cells [25, 26] . Prestimulation with a cocktail of five cytokines containing fms-like tyrosine kinase 3 (Flt-3) ligand, stem cell factor (SCF), interleukin (IL)-6, HGF, and IL-3 promotes the migration of FLK(+) MSCs to the bone marrow through up-regulation of both cell surface and intracellular CXCR4 [71] . Other factors, such as IGF-1 [72, 73] , IL 1β [74] , interferon γ (IFNγ) [4, 75] , basic fibroblast growth factor (bFGF), PDGF [41] , nitric oxide donor [76] , or complement 1q (C1q) [77] have also been shown to improve MSC homing in different disease models possibly as a result of increased CXCR4 or MMP expression. Pretreating MSCs with a combination of hematopoietic growth factors erythropoietin (EPO) and granulocyte colony stimulating factor (G-CSF) can enhance their motility by increasing the MMP expression [78] . Tsai et al. showed that priming with valproate and/or lithium resulted into robust migration and homing of the MSCs towards the sites of ischemia in models of stroke and Huntington's disease [79, 80] . The underlying mechanism may involve an increase in CXCR4 expression by histone deacetylase (HDAC) inhibition, or elevation in MMP-9 levels through glycogen synthase kinase-3β inhibition. The treatment of MSCs with deferoxamine (DFO), cobalt chloride, or hydralazine can lead to increased surface expression of HIF-1a proteins, resulting in transcription of genes involved in cell migration [81] [82] [83] [84] . In addition, pretreatment with all-trans retinoic acid [85] , melatonin [86] , estrogen receptorα (ERα) [87] , and certain extracts from traditional Chinese herbs (i.e. Polydatin [88] and Exenatide [89] ) can enhance the migration of MSCs as well [90] . Ro-31-8425, a kinase inhibitor identified as the most potent inducer of the homing integrin CD11a (integrin αL) surface expression, can significantly increase firm adhesion of MSCs to the endothelial ligand of CD11a, ICAM-1. In addition, it has been found that systemically infused MSCs pretreated with Ro-31-8425 display improved homing to the sites of inflammation and a stronger anti-inflammatory effect in a murine model of ear inflammation [90, 91] . Pretreating MSCs with cytokines and small molecules to control cell homing possesses multiple advantages over other bioengineering approaches. Cytokine-and small molecule-induced transient modifications of signaling pathways offer a potentially safe, simple, cost-effective, and highly scalable approach. Certain molecules, such as bFGF [92] and retinoic acid [93] [94] [95] , can also promote differentiation of MSCs into neurons. While a few other molecules may change the differentiation and proliferation properties of the cell, such effects of most methods are thought to be negligible.
Genetic modification of MSCs
SDF-1α/CXCR4 axis is one of the most important chemokine/receptor complexes regulating migration. Numerous experiments in which MSCs were modified by increasing the expression of the CXCR4 gene resulted in higher density of CXCR4 receptor, increased migration of MSCs toward SDF-1, and higher affinity to migrate to the sites of lesion [96] . In a rat model of cerebral ischemia, CXCR4 overexpression in the rMSCs promoted their mobilization and enhanced neuroprotective effects [97] . Apart from CXCR4, SDF-1 can also bind to CXCR7. Therefore, overexpressing CXCR7 receptor enhances migration as described above in cases of CXCR4 overexpression [98, 99] . In addition, overexpressing CXCR1, the receptor for IL-8, also improves migration [100] . Aquaporin-1 (Aqp1), the channel protein that transports water across the cell membrane, has been shown to interact with β-catenin to regulate cell migration. Therefore, MSCs overexpressing Aqp1 showed increased migration toward the sites of injury [101] . In addition, certain studies have shown that increased expression of nuclear factors, Nur77 and Nurr1 [102, 103] , and Sox11 [104] or the overexpression of a4 subunit of the VLA-4 integrin [105] lead to enhanced cellular migration. In order to enhance the migration through vessel walls, MSCs were simultaneously transfected with mRNAs for P-selectin glycoprotein ligand-1 (PSGL-1) and Sialyl-Lewis(x) (SLeX). These cells produced functional ligands for P-selectins and E-selectins, resulting in significantly enhanced MSC homing to the inflamed spinal cord during experimental autoimmune encephalomyelitis (EAE) in mice [106] . Recently, microRNAs (miRNAs) have been described as regulators of MSC migration. The overexpression of miR-221 [107, 108] or miR-26b [108] enhanced MSC migration through the activation of PI3K/Akt signaling. Genetic engineering, therefore, is a more directed method to promote migration, but this technique is difficult and expensive. In addition, the risk of tumorigenicity cannot be excluded.
Cell surface engineering of MSCs
A new method that consists in coating MSCs with antibodies against addressins has been used to enhance the homing of these cells to the colon and increase the therapeutic efficacy in inflammatory bowel disease (IBD). It has been shown that vascular cell adhesion molecule antibody (Ab)-coated MSCs (Ab(VCAM-1)-MSCs) have the highest homing efficiency compared to untreated MSCs, Ab(isotype)-MSCs, and Ab(MAdCAM)-MSCs [109] .
Since rolling is one of the first steps in the homing phase, an easy and generic approach to promote this process is to transiently engineer the cell surface using lipid vesicles. It was demonstrated that lipid vesicles could rapidly fuse with the cell membrane to introduce biotin moieties on the cell surface. Biotin can subsequently bind streptavidin and potentially any biotinylated homing ligand. The immobilization of sialyl Lewis X (SLeX) on MSCs to induce cell rolling on a P-selectin surface was significantly improved through a biotin-streptavidin bridge [110, 111] . While MSCs do not express E-selectin ligands, they highly express a CD44 glycoform bearing a-2,3-sialyl modification. The native CD44 glycoform on MSCs can be converted to a ligand for E-selectin by treatment with a-1,3fucosyltransferase under specific enzymatic conditions without affecting cell viability or multipotency. Such modification of CD44 with an E-selectin binding motif increased specific homing of MSC to the BM [50, 65] . While cell surface engineering is a novel method to enhance migration in a controlled manner, the cost of this technique is elevated.
Physical stimulation of MSCs (light, electricity, and sound)
Several studies have evaluated the effects of photobiomodulation (PBM) on the migration of MSCs. After irradiation of hMSCs in vitro by low level lasers (LLL), cell migration was accelerated via ERK1/2 and FAK pathway and upregulation of the expression of growth factors such as HGF and PDGF [112] . Electrical fields (EFs) were shown to induce rapid and directed migration of neural precursor cells [113, 114] . Griffin et al. found that BMSCs treated by EFs showed significantly increased expression of several migration-related molecules, including SDF-1/CXCR4, PDGF-BB-R, TGFbR1, IGF-1/IGF-1R, MMP-2, and MT1-MMP [115] . Besides, it has been found that defocused low-energy shock wave (DLSW) can activate MSCs. While treating rat adipose tissue-derived stromal cells (ADSCs) with DLSW did not alter the morphology and phenotype of ADSCs, the secretion, proliferation, and migration of ADSCs were promoted [36] . Thus, physical stimulation provides new means of improving the efficiency of cell therapy in the future.
Methods to promote the homing of MSCs in the treatment of CNS disorders
MSCs have been used to treat various CNS disorders in preclinical and clinical studies, such as spinal cord and traumatic brain injury [116] [117] [118] , ischemic stroke [31, 40, 56, 62, 69, 97, [119] [120] [121] [122] [123] , intracranial hemorrhage (ICH) [124] , Parkinson's disease [125, 126] , multiple sclerosis [127] , experimental autoimmune encephalomyelitis (EAE) [47, 128, 129] , amyotrophic lateral sclerosis [130, 131] , Alzheimer's disease [132] , Huntington's disease [133] [134] [135] , and so on. Potential repair mechanisms involve transdifferentiation to replace damaged neural cells and production of growth factors by MSCs. In addition, infused MSCs could modulate inflammation and stimulate endogenous neural stem cells to migrate to the target region [10, 106, 116, 136, 137] . The major obstacles for cell therapies are limited cell availability and engraftment, as well as reduced integration of grafted cells into the host tissue [138] . Apart from the abovementioned strategies to improve the migration of MSCs following cell therapy, several specific methods to enhance engraftment in the CNS have been tested. The efficiency of cell-based therapies for neurodegenerative diseases largely depends on the mode of cell administration [139] . The IV (intravenous) route of administration has advantages of being more convenient, less invasive, and safer than intrathecal and intracerebral routes of administration [140] , but the homing of the cells is limited. Administration of cells through intra-arterial injection during acute stroke resulted into a higher efficiency of cerebral engraftment [61] . In addition, it has been hypothesized that intranasally administered cells can bypass the bloodbrain barrier by migrating from the nasal mucosa through the cribriform plate along the olfactory neural pathway into the brain and cerebrospinal fluid (CSF). This method would minimize or eliminate the distribution of cellular grafts to peripheral organs and facilitate neurosurgical cell implantation [139] . Several studies have proven that intranasal transplantation promotes migration of infused MSCs to the sites of lesion [141, 142] . Blood brain barrier (BBB), consisting of cellular interactions between brain microvascular endothelial cells (BMECs), astrocytes, pericytes, and neurons [143] , may restrict the number of stromal cells reaching injury sites. Whether systemically infused MSCs can actively migrate across BBB is still unclear. Rat MSCs were found to transmigrate across the BMEC monolayers in vitro through transient intercellular gaps between the BMECs [144] . However, the molecular mechanism underlying MSCs-BBB interaction is not known. It seems that MSCs undergo a leukocyte-like multistep homing cascade (i.e., rolling, adhesion, and transmigration) to engage with endothelial cells (ECs) [145] . Some studies indicate that MSCs may induce the disassembly of tight junctions in HBMEC through ERK1/2, PI3K, and ROCK signaling pathways [146, 147] . Since in vitro studies are performed using EC monolayers that do not fully recapitulate the in vivo BBB properties, further in vivo research is needed.
Crossing the BBB may be a prerequisite for MSCs to exert their therapeutic effects in treating neurological diseases [11, 145] . Thus, increasing the permeability of BBB appears as a feasible option to improve MSCs homing. Currently existing strategies for BBB opening are invasive, unspecific, and lack precise control over the site and timing of BBB opening. These disadvantages may limit their clinical translation. A novel approach has been described based on a combination of stromal cell delivery, heat-inducible gene expression, and mild heating with high-intensity focused ultrasound (HIFU) under MRI guidance to remotely permeabilize the BBB [148] . The principle of this method is to administrate stromal cells engineered to express pro-inflammatory factors that will permeabilize the BBB but only trigger their expression after heating with non-invasive imageguided HIFU. The aim of using this approach is to achieve a non-invasive way for BBB opening to restrict to the site where selected pro-inflammatory factors are secreted secondary to HIFU activation. This novel manner of BBB opening with unprecedented spatiotemporal precision may become an excellent method of improving the engraftment of stromal cells in the future.
Tracking migration and distribution of implanted MSCs
Migration and precise location of infused MSCs can be tracked by several in vivo imaging methods including MRI, SPET/CT, and PET [11, [149] [150] [151] . In animal models, we can also track the cells by using techniques of fluorescent labeling [152] [153] [154] [155] , transduction of MSCs with reporter genes [59] , taking advantage of species or sex mismatch by using specific genes as markers by fluorescent in situ hybridization or real-time PCR [11, 24] . In addition, nanoparticles have been used as a noninvasive technique of in vivo cellular tracking in cell therapy. Biocompatible superparamagnetic iron oxide nanoparticles (SPIONs) appear promising in investigation of homing, biodistribution, and fate of transplanted cells in preclinical and clinical studies because of their slower renal clearance, higher relaxation values, and low toxicity [156, 157] . Recently, a simple and well controlled stem cell imaging method was developed using imageable nanoparticles that bind bioorthogonal chemical receptors on the stromal cell surface [158] . These labeled stromal cells can be continuously tracked by noninvasive optical imaging over 15 days, and higher endocytic capacity can be achieved as compared with non-specific uptake of nanoparticles. Besides nanoparticles, a cellular barcoding tool was recently reported to enable clonal tracking in the hematopoietic system [159] . A small unique sequence or barcode was inserted into the genome of each individually hit cell through retroviral system. The progeny of all labeled cells can be traced as daughter cells carry the same barcode as mother cells [160] . This method might potentially provide a better clinical tool for studying the fate of transplanted MSCs. In addition, micro-optical sectioning tomography (MOST), a new imaging technique, is an attractive option for future studies of stromal cell migration. The MOST system consists of a microtome, light microscope, and image recorder, and it can perform imaging and sectioning simultaneously [161] . Combined with fluorescence imaging, the fluorescence micro-optical sectioning tomography (fMOST) has been used for whole mousebrain imaging to acquire sets of data relative to multiple types of neurons and projections. This technique has a single-neuron resolution and allows for precise tracing of long-range projections and accurately locating the nuclei [162] [163] [164] . We have used fMOST to image the neurons and microvessel density in a model of ICH [165] . Use of fMOST may provide novel means for exploring the migration and distribution of transplanted stromal cells in addition to study the formation of new neural circuits during brain inflammation and injury repair.
Summary and Prospective
MSCs have been widely tested as a potential treatment for various diseases because of convenient isolation, less ethical issues, and low/negligible immunogenicity [11] . Low rates of cell homing, retention, and survival are the major limitations in current experimental and clinical studies for all different types of MSCs available [11, 15, 24, 138] . Many factors can influence the homing of MSCs (see Table 1 ). In this review, we have mainly discussed the potential roles of chemokines, growth factors, adhesion molecules, and MMPs in the process of migration. We then summarized the existing strategies to promote stromal cell migration (see Table 2 ). Finally, we discussed the migration of MSCs in the treatment of CNS diseases. Pretreatment with various small molecules and culturing cells under hypoxic environment has been shown to effectively improve MSC migration, and these methods are simple and cheap. However, these pretreatments may change certain properties of the original cells, and some of them show limited effects. Genetic modifications and cell surface engineering appear more efficient in improving cell homing. However, the difficulty and the cost of these techniques are elevated. In addition, unwanted genes may be introduced causing a series of safety problems. As for the physical stimulation of MSCs by light, sound, and electrical fields, this strategy may represent a new promising method to improve the efficiency of cell therapy in the future. When MSCs are used to treat CNS diseases, lower number of infused cells reaches the sites of lesion due to the existence of BBB. Adequate administration routes, such as intra-arterial and intranasal delivery of stromal cells can lead to improved cerebral engraftment via reducing cell entrapment by the liver, spleen, and lungs or by bypassing the blood-brain barrier. Recently, a new method based on a combination of stromal cell delivery, heat-inducible gene expression, and mild heating with high-intensity focused ultrasound (HIFU) was found to precisely and non-invasively permeabilize the BBB. Our aim is to achieve increased homing and engraftment of MSC while using lower doses of transplanted cells, thereby decreasing the duration of cell culture, costs, availability, and the risk of transformations during culture expansion [160] . However, these trials should not compromise the viability, proliferation, and differentiation ability of the cells. A meta-analysis of preclinical results examining the intravenous route of cell delivery for the treatment of neurological disorders showed a good correlation between the dose of infused cells and the therapeutic effect. As such, correlation has not been shown between the therapeutic outcome and the number of cells engrafted within the lesioned brain area [166] , different therapeutic mechanisms unrelated to the presence of infused cells within the injury site probably underlie the therapeutic effect. Recently, extracellular vesicles (EVs), membrane-surrounded structures released by most cell types, have been recognized as potent vehicles of intercellular communication that transmit biological signals between the cells. Paracrine effects of MSCs may be mediated by EVs [136] . The stromal cell derived-EVs do not replicate like the stromal cells, and they are less likely to become trapped inside the lungs after intravenous administration. In addition, given that exosomes, a subtype of secreted vesicles, are lipidbound nano-vesicles, they act as liposomes and can cross the blood-brain barrier [167] . Therefore, exosomes may represent an attractive therapeutic option for CNS disorders in the future. 
